Latest market price
8.41
-3.16-27.31%
OverviewShort InterestFilings
CMPSQT39COMPASS Pathways plc·NASDAQ
8.41-27.31%
Earnings
Down 27.3% — Reported earnings — EPS beat by 7%.
High confidence
TA
Loading chart...
Signal & projected range
QT Score downgradeHistorical pattern — not a prediction
Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE-7.49%$22.97RARE+1.24%$16.30NUVB-3.57%$4.59TRAX-0.07%$45.05NTLA-6.50%$11.66ABSI-12.94%$9.69URGN+5.01%$34.36MAZE-3.53%$30.37
Snapshot
Index—P/E—EPS (ttm)-5.57Insider Own12.26%Shs Outstand138.48MPerf Week-23.89%
Market Cap1.16BForward P/E—EPS next Y-1.66Insider Trans0.00%Shs Float136.24MPerf Month-29.33%
Enterprise Value784.59MPEG—EPS next Q-0.39Short Float12.97%Perf Quarter-28.73%
Income-395.00MP/S—EPS this Y—Short Ratio6.42Perf Half Y-11.66%
Sales0.00P/B13.70EPS next Y—ROA-78.12%Short Interest17.67MPerf YTD21.88%
Book/sh0.61P/C2.69EPS next 5Y—ROE-398.21%52W High15.87 -47.01%Perf Year33.49%
Cash/sh3.13P/FCF—EPS past 3/5Y—ROIC-129.74%52W Low4.88 72.34%Perf 3Y54.03%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility11.88% 6.63%Perf 5Y-78.05%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)0.91Perf 10Y—
Dividend Ex-Date—Quick Ratio1.30Sales Y/Y TTM—Profit Margin0.00%RSI (14)28.09Recom2.00
Dividend Gr. 3/5Y—Current Ratio1.30EPS Q/Q5.26%SMA20-26.23%Beta2.41Target Price18.63
Payout0.00%Debt/Eq0.62Sales Q/Q—SMA50-34.35%Rel Volume5.82Prev Close11.57
Employees156LT Debt/Eq0.62EarningsNov 03SMA200-19.18%Avg Volume2.88MPrice8.41
IPO DateSep 18, 2020Option/ShortYes / YesEPS/Sales Surpr.7.25% —Net Debt/EBITDA—Volume16,791,872Change-27.31%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-27-26InitiatedWells FargoEqual Weight$13
Jul-20-26ReiteratedB.Riley Financial$17
Jul-08-26UpgradeEvercore ISI GroupIn Line → Outperform
Jul-07-26ReiteratedStifel Nicolaus$21
Jul-07-26ReiteratedCompass Point$15 → $25
May-15-26ReiteratedMaxim GroupBuy$20
May-14-26ReiteratedMorgan StanleyOverweight$18 → $17
May-07-26InitiatedUBS$17 → $18
May-03-26InitiatedJefferiesBuy$18
Apr-24-26InitiatedB. RileyBuy$17
Latest News· Times ET
Nov-02-26
Nov-02-2606:30AM
New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregiversbusinesswire.com
03:30AM
1 Reason Compass Pathways Is Worth a Second Look This Monthfool.com
Oct-29-26
Oct-29-2608:27AM
'New Bill In Congress Would Dramatically Overhaul How The Federal Government Classifies Drugs While Legalizing Marijuana' - Marijuana MomentBenzinga
Oct-28-26
Oct-28-2606:30AM
Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congressbusinesswire.com
01:11AM
Compass Pathways: A Compelling Opportunity In A Large And Underserved Marketseekingalpha.com
Oct-27-26
Oct-27-2606:30AM
Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026businesswire.com
Oct-21-26
Oct-21-2602:04PM
Cybin Eyes Q4 Phase III Depression Data as Anxiety Program AdvancesYahoo
10:17AM
Compass Pathways: Built The FDA's Way, Valued At 0.57x Spravato's Salesseekingalpha.com
Oct-17-26
Oct-17-2609:09PM
COMPASS Pathways (CMPS) Stock May Trade At A Premium After Positive Phase 3 ResultsYahoo
Oct-14-26
Oct-14-2606:30AM
Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Daybusinesswire.com
Oct-07-26
Oct-07-2611:23PM
Compass Pathways Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga
Oct-02-26
Oct-02-2606:30AM
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo
Oct-01-26
Oct-01-2604:29AM
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Has Consensus Target Price of $23.36 According to Brokeragesdefenseworld.net
Sep-30-26
Sep-30-2606:30AM
Compass Pathways Appoints Kelley Boucher as Chief People Officerbusinesswire.com
Sep-24-26
Sep-24-2608:02PM
Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 LaunchYahoo
Company

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue
0000—————
Cost of Goods Sold Incl. D&A
0000—————
Gross Profit
0000—————
Selling, General and Administrative Excl. Other68615949—————
Research and Development10811811988—————
Other Operating Expense
6000—————
Operating Income-182-179-178-137—————
Interest Expense4542—————
Unusual Expense
—————————
Non-Operating Income (Expense)-210-1072921—————
Net Income Before Taxes-397-290-154-118—————
Income Taxes-3-221—————
Consolidated Net Income-395-288-155-118—————
Net Income From Continuing Operations-395-288-155-118—————
Net Income-395-288-155-118—————
EPS (Recurring)-5.57-3.08-2.30-2.32—————
EPS (Basic, Before Extraordinaries)-5.57-3.08-2.30-2.32—————
EPS (Diluted)-5.57-3.08-2.30-2.32—————
EBITDA-391-286-149-115—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding94946751—————
Market Capitalization791649253446—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$16.81$13.31$9.80$6.30$2.80● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Malievskaia Ekaterina10% OwnerOct 24 '24Sale0.001,553,13003,152,848Oct 25
Goldsmith George Jay10% OwnerOct 24 '24Sale0.001,553,13003,152,848Oct 25
ATAI Life Sciences N.V.10% OwnerSep 26 '24Sale6.052,660,00016,093,0006,905,774Sep 27
Goldsmith George Jay10% OwnerMay 21 '24Sale7.9117,800140,7583,929,413May 22
Malievskaia Ekaterina10% OwnerMay 21 '24Sale7.9117,800140,7583,929,413May 22
Goldsmith George Jay10% OwnerMay 20 '24Sale7.8913,407105,8083,938,313May 22
Malievskaia Ekaterina10% OwnerMay 20 '24Sale7.8913,407105,8083,938,313May 22
Goldsmith George Jay10% OwnerMay 03 '24Sale8.8237,523330,9043,945,017May 06
Malievskaia Ekaterina10% OwnerMay 03 '24Sale8.8237,523330,9043,945,017May 06
Goldsmith George Jay10% OwnerMay 02 '24Sale8.2919,243159,5283,963,778May 06
Malievskaia Ekaterina10% OwnerMay 02 '24Sale8.2919,243159,5283,963,778May 06
Goldsmith George Jay10% OwnerApr 17 '24Sale8.7821,700190,6143,973,400Apr 18
Malievskaia Ekaterina10% OwnerApr 17 '24Sale8.7821,700190,6143,973,400Apr 18
Malievskaia Ekaterina10% OwnerApr 16 '24Sale8.5347,761407,3493,984,250Apr 18
Goldsmith George Jay10% OwnerApr 16 '24Sale8.5347,761407,3493,984,250Apr 18
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.